KMB

Business Context and Reporting Period

Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: The Corporation operates four global business segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The company is executing a multi-year strategic cost reduction plan aimed at streamlining operations and improving margins.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8.2% in Q2 2007 and 8.0% YTD, driven by volume growth (approx. 4%), price increases (1%), and favorable currency effects (3%).
• Profitability: Operating profit rose 19.2% in Q2 and 31.1% YTD. The YTD increase was significantly aided by a $240 million reduction in strategic cost reduction charges compared to the prior year.
• Segment Performance:
  • Personal Care: Sales up 9.7% (Q2) driven by volume and currency; operating profit up 19.7%.
  • Consumer Tissue: Sales up 9.4% (Q2); operating profit declined 4.9% due to raw material inflation and higher marketing expenses.
  • Health Care: Sales down 6.6% (Q2) due to volume declines in exam gloves (transition from latex to nitrile) and lower face mask sales compared to the prior year's avian flu demand.
• Cost Inflation: Raw material costs increased approximately $85 million in Q2, primarily due to higher fiber costs ($55 million).
• Tax Rate: The effective income tax rate decreased to 20.0% in Q2 2007 from 26.8% in 2006, largely due to higher synthetic fuel tax credits.

Guidance, Outlook, and Risks

• Strategic Cost Reduction Plan: The company expects cumulative pretax charges of $875 million to $925 million by the end of 2008 (revised down from previous estimates). The plan targets annual pretax savings of at least $350 million in 2009. Full-year 2007 pretax charges are expected to total approximately $120 million.
• Capital Spending: Expected to total $900 million to $1 billion for 2007.
• Share Repurchases: The company announced a new $2 billion accelerated share repurchase agreement (ASR) in July 2007. The full-year 2007 repurchase target was raised to $2.8 billion.
• Outlook: Management expects to overcome inflationary pressures through price realization and cost savings. Health Care sales comparisons are expected to improve in the second half of the year as nitrile glove demand grows.
• Risks and Contingencies:
  • Legal: A subsidiary is involved in litigation with Delcora regarding alleged underreporting of wastewater effluent; management does not expect a material adverse effect.
  • Tax: Adoption of FIN 48 resulted in a $34.2 million decrease in retained earnings. Approximately $490 million in unrecognized tax benefits remain, with transfer pricing being the most significant uncertainty.
  • Accounting Correction: The company corrected a presentation error regarding the SFAS 158 transition adjustment, which previously reduced 2006 comprehensive income by $395.2 million incorrectly.

Investor Verification Checklist

• Raw Material Costs: Verify the sustainability of margin improvements given the $85 million Q2 inflation in fiber and nonwoven costs.
• Health Care Segment: Monitor the transition from latex to nitrile exam gloves to confirm if volume declines stabilize in the second half of 2007.
• Strategic Cost Reductions: Track the realization of the targeted $350 million annual savings by 2009 against the revised total charge estimate of $875-$925 million.
• Share Repurchase Execution: Confirm the execution of the $2 billion accelerated share repurchase and the impact on diluted share count.
• Tax Liabilities: Review the status of the $490 million in unrecognized tax benefits and potential settlements related to transfer pricing.